

Special Issue

Tumor Microenvironment and Treatment Resistance

Message from the Guest Editor

Cancer cells can resist therapeutic interventions through innate or acquired mechanisms, posing a significant challenge to chemotherapy, radiation and targeted therapy. Both primary and metastatic sites can contribute to cancer cell resistance via cell intrinsic and extrinsic factors, with the latter often overlooked. Recent studies have initiated the exploration of the complex relationship between cancer resistance and TME in pathological conditions. The findings suggest that the tumor microenvironment plays a crucial role in regulating immune escape, progression and distant metastasis of cancer. Although chemotherapy and radiotherapy have made considerable progress, the emergence of therapeutic resistance limits their effectiveness. This Special Issue focuses on how the interplay between tumor cells and the surrounding cells in the microenvironment poses treatment resistance. The aim is to collect new ideas, concepts and findings in the field of cancer (e.g., epigenetics, immunosuppression, drug delivery and penetration, etc.) and treatment strategies (e.g., nanomedicine, immunotherapy, etc.).

Guest Editor

Prof. Dr. Zahid Pranjol

School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9RH, UK

Deadline for manuscript submissions

closed (31 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/162589

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)